Washington, DC – The Global CEO Initiative on Alzheimer’s Disease (CEOi), Sage Bionetworks and DREAM Project, today launched the Alzheimer’s Disease Big Data DREAM Challenge #1 in an effort to advance diagnostic innovation and identify new Alzheimer’s disease biomarkers through the use of open source data.
The goal of the Challenge (AD#1) is to apply an open science approach to rapidly identify accurate predictive Alzheimer’s disease biomarkers that can be used by the scientific, industry and regulatory communities to improve Alzheimer’s diagnosis and treatment. AD#1 will be the first in a series of Alzheimer’s Data Challenges to leverage genetics and brain imaging in combination with cognitive assessments, biomarkers and demographic information from cohorts ranging from cognitively normal to mild cognitively impaired to individuals with Alzheimer’s.
“Alzheimer’s is more costly to society than cancer, yet there is currently no cure, treatment, or means of prevention” said George Vradenburg, Convener of CEOi and Chairman of USAgainstAlzheimer’s. “This unprecedented and innovative challenge will showcase the use of open science using 21st century tools, leading to a potential breakthrough for the Alzheimer’s research community.”
The AD#1 Challenge is hosted on Synapse, Sage Bionetworks’ open computational platform, an integrated knowledge environment where data (e.g. human sequence and image data) and models (e.g. prediction and the underlying model source code) can be shared and worked on collaboratively by teams of teams. The Challenge will be objectively judged against data that has been hidden from participants. Information about the three AD#1 Challenge questions and the scientific rationale can be found here.
“This challenge will showcase the power of open science in breaking down barriers that slow innovation in the race to cure Alzheimer’s,” said Stephen Friend, President and Co-Founder of Sage Bionetworks. “Through this series of big challenges, we hope to move closer to solving this intractable problem of Alzheimer’s.”
The open source data from Alzheimer’s patients is provided by the North American Alzheimer’s Disease Neuroimaging Initiative (ADNI), Rush University Medical Center, and the United Kingdom’s AddNeuroMed Study, and will include results from imaging, clinical, whole genome sequencing, and multiple cognitive tests that were conducted on a cohort of individuals who have aged normally, suffer from mild-cognitive impairment or have Alzheimer’s disease. More than two hundred bioinformatics experts from around the world have already signed up to participate in the Challenge.
While there has been huge growth in scientific data due to declining costs and advances in technology, there remains very little crowd sourcing of findings among researchers. In recent years, however, pharmaceutical companies have shown an increased willingness to share pre-competitive data, as research and development has declined. This development has occurred alongside recent efforts by regulatory agencies to encourage data standardization, disclosure, and sharing.
More than 40 million people globally suffer from Alzheimer’s disease or dementia. Today, the global cost of caring for people with Alzheimer’s is more than 1% of global economic output, or $600 billion annually. In coming years, as more and more baby boomers reach the age of risk for the disease, those numbers are projected to skyrocket without a treatment to slow the progression of the disease.
Through its diverse partnerships, the CEOi is seeking to work closely with governments and global institutions to advance meaningful reforms to the Alzheimer’s drug marketplace. The CEOi members include AC Immune, Bank of America, Banner Health, General Electric, Home Instead, Janssen, Lilly, Merck, Nestle Health Science, Pfizer, Sanofi, and Takeda.
Global CEO Initiative on Alzheimer’s Disease (CEOi) is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer’s. The CEO Initiative seeks to partner with public leaders to transform the disease from a social, health, and economic crisis into an opportunity for healthy aging and innovation in research and care. The CEO Initiative believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. Learn more at: www.ceoalzheimersinitiative.org.
Sage Bionetworks is a nonprofit biomedical research organization, founded in 2009, with a vision to promote innovations in personalized medicine by enabling a community-based approach to scientific inquiries and discoveries. Sage Bionetworks strives to activate patients and to incentivize scientists, funders and researchers to work in fundamentally new ways in order to shape research, accelerate access to knowledge and transform human health. It is located on the campus of the Fred Hutchinson Cancer Research Center in Seattle, Washington and is supported through a portfolio of philanthropic donations, competitive research grants, and commercial partnerships. More information is available at www.sagebase.org.
The goal of the Alzheimer’s Disease Big Data DREAM Challenge #1 (AD#1) is to apply an open science approach to rapidly identify accurate predictive AD biomarkers that can be used by the scientific, industrial and regulatory communities to improve AD diagnosis and treatment. AD#1 will be the first in a series of AD Data Challenges to leverage genetics and brain imaging in combination with cognitive assessments, biomarkers and demographic information from cohorts ranging from cognitively normal to mild cognitively impaired to individuals with AD.
We invite you to participate in this Challenge by considering any of the following questions:
Subchallenge 1: Predict the change in cognitive scores 24 months after initial assessment.
Scientific Rationale: Answers to this question will help predict cognitive trajectory and potentially provide new approaches for early diagnosis of AD. This earlier identification would allow for more efficient selection of samples for clinical trials and possibilities for earlier disease treatment.
Subchallenge 2: Predict the set of cognitively normal individuals whose biomarkers are suggestive of amyloid perturbation.
Scientific Rationale: Answers to this question will help us understand how some people maintain normal cognitive function in the presence of amyloid pathology. The biological basis of this resilience to pathology will provide important insights into the development of prevention and therapy.
Subchallenge 3: Classify individuals into diagnostic groups using MR imaging.
Scientific Rationale: If a single MR image could be used to differentiate AD patients from people with mild cognitive impairment or from healthy individuals, research can focus on the specific anatomical structures that are different between the groups. Currently, MRI data are acquired routinely in hospitals: thus a winning algorithm could potentially be retrospectively applied to existing archives of clinical data as well as to future scans without requiring additional resources or expertise.
For questions about the Challenge design please contact thethrough the